English

Interim report January – June 2013

Report this content

Continuing good performance

Second quarter:

Continuing operations

  • Sales growth was 29 percent in local currency. Sales amounted to SEK 116 (95) million, corresponding to an increase of 22 percent in SEK.
  • Operating income (EBIT) amounted to SEK 19 (13) million, corresponding to an operating margin of 16 (13) percent.
  • The comparative figures for 2012 relate to continuing operations, fertility, unless otherwise stated.
  • Net income amounted to SEK 12 (11) million, which gave earnings per share of SEK 0.62 (0.54).
  • Dividend of SEK 0.60 (0.60) per share, in total SEK 11,898,562 (11,737,661).
  • On April 1, 2013 Vitrolife exercised an option to acquire all the shares in HertArt ApS.

First half year:

Continuing operations

  • Sales growth was 28 percent in local currency. Sales amounted to SEK 221 (181) million, corresponding to an increase of 22 percent in SEK.
  • Operating income (EBIT) amounted to SEK 36 (23) million, corresponding to an operating margin of 16 (13) percent.
  • The comparative figures for 2012 relate to continuing operations, fertility, unless otherwise stated.
  • Net income amounted to SEK 24 (18) million, which gave earnings per share of SEK 1.22 (0.92).

Gothenburg, July 12, 2013

VITROLIFE AB (publ)

Thomas Axelsson, CEO

Queries should be addressed to:

Thomas Axelsson, CEO, tel 46 31 721 80 01

Mikael Engblom, CFO, tel 46 31 721 80 14

Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on July 12, 2013 at 08:30 a.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

_________________________________________________________________________________________________________________

Vitrolife is an international medical device Group. Vitrolife Fertility product area develops, produces and markets medical devices for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife has approximately 230 employees and the company's products are sold in almost 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China, Japan, Hungary and Denmark. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.

_________________________________________________________________________________________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/

Tags:

Interim report quarterly report Vitrolife fertility VitrolifeConception Technologies IVF IVF Mikael Engblom Vitrolife IVF Thomas Axelsson Carsten Browall

Subscribe

Documents & Links